Genovis AB logo

GENO - Genovis AB Share Price

SEK36.1 0.4  1.0%

Last Trade - 2:03pm

Small Cap
Market Cap £208.1m
Enterprise Value £202.8m
Revenue £5.28m
Position in Universe 588th / 1782
Unlock GENO Revenue
Relative Strength (%)
1m +4.11%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -9.03%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
8.25 13.3 18.5 22.9 34.6 60.5 53.0 108 +49.0%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Genovis AB revenues decreased 4% to SEK11.5M. Net loss totaled SEK2M vs. income of SEK1.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Personnel costs increase of 28% to SEK6.1M (expense), Other External Expenses increase of 19% to SEK4.4M (expense), Depreciation & Amortization increase of 38% to SEK1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for GENO
Graphical History


GENO Revenue Unlock GENO Revenue

Net Income

GENO Net Income Unlock GENO Revenue

Normalised EPS

GENO Normalised EPS Unlock GENO Revenue

PE Ratio Range

GENO PE Ratio Range Unlock GENO Revenue

Dividend Yield Range

GENO Dividend Yield Range Unlock GENO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
GENO EPS Forecasts Unlock GENO Revenue
Profile Summary

Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Public Since November 11, 2005
No. of Shareholders: n/a
No. of Employees: 26
Sector Healthcare
Industry Healthcare Equipment & Supplies
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 66,261,714
Free Float (0.0%)
Eligible for
GENO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for GENO
Upcoming Events for GENO
Frequently Asked Questions for Genovis AB
What is the Genovis AB share price?

As of 2:03pm, shares in Genovis AB are trading at SEK36.1, giving the company a market capitalisation of £208.1m. This share price information is delayed by 15 minutes.

How has the Genovis AB share price performed this year?

Shares in Genovis AB are currently trading at SEK36.1 and the price has moved by 0.102k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Genovis AB price has moved by 0.111k% over the past year.

What are the analyst and broker recommendations for Genovis AB?

Of the analysts with advisory recommendations for Genovis AB, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Genovis AB is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Genovis AB next release its financial results?

Genovis AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Genovis AB dividend yield?

Genovis AB does not currently pay a dividend.

Does Genovis AB pay a dividend?

Genovis AB does not currently pay a dividend.

When does Genovis AB next pay dividends?

Genovis AB does not currently pay a dividend.

How do I buy Genovis AB shares?

To buy shares in Genovis AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Genovis AB?

Shares in Genovis AB are currently trading at SEK36.1, giving the company a market capitalisation of £208.1m.

Where are Genovis AB shares listed? Where are Genovis AB shares listed?

Here are the trading details for Genovis AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: GENO
What kind of share is Genovis AB?

Based on an overall assessment of its quality, value and momentum, Genovis AB is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Genovis AB share price forecast 2020?

Shares in Genovis AB are currently priced at SEK36.1. At that level they are trading at 28.67% discount to the analyst consensus target price of 0.00.

Analysts covering Genovis AB currently have a consensus Earnings Per Share (EPS) forecast of -0.06 for the next financial year.

How can I tell whether the Genovis AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genovis AB. Over the past six months, the relative strength of its shares against the market has been 79.76%. At the current price of SEK36.1, shares in Genovis AB are trading at 34.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Genovis AB PE Ratio?

The Genovis AB PE ratio based on its reported earnings over the past 12 months is 0.375k. The shares are currently trading at SEK36.1.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Genovis AB?

Genovis AB's management team is headed by:

Sarah Fredriksson - CHM
Fredrik Olsson - CEO
Kenth Petersson - DRC
Mikael Lonn - DRC
Marten Winge - CHM
Lena Soderstrom - DRC
Peter Hein - DRC
Lotta Ljungqvist - DRC
Johny Humaloja - CFO
Who are the major shareholders of Genovis AB?

Here are the top five shareholders of Genovis AB based on the size of their shareholding:

TIN Fonder Investment Advisor
Percentage owned: 3.77% (2.47m shares)
Ny Teknik Mutual Fund
Percentage owned: 3.77% (2.47m shares)
Aktia Asset Management Oy Ab Investment Advisor
Percentage owned: 3.38% (2.21m shares)
Swedbank Robur Fonder AB Investment Advisor/Hedge Fund
Percentage owned: 2.33% (1.52m shares)
Handelsbanken MicroCap Sverige Mutual Fund
Percentage owned: 2.29% (1.50m shares)
Similar to GENO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.